WO2011014850A3 - Topical eutectic-based formulations - Google Patents

Topical eutectic-based formulations Download PDF

Info

Publication number
WO2011014850A3
WO2011014850A3 PCT/US2010/044036 US2010044036W WO2011014850A3 WO 2011014850 A3 WO2011014850 A3 WO 2011014850A3 US 2010044036 W US2010044036 W US 2010044036W WO 2011014850 A3 WO2011014850 A3 WO 2011014850A3
Authority
WO
WIPO (PCT)
Prior art keywords
eutectic
methods
based formulations
topical
provides
Prior art date
Application number
PCT/US2010/044036
Other languages
French (fr)
Other versions
WO2011014850A2 (en
Inventor
Servet Buyuktimkin
Nadir Buyuktimkin
Jagat Singh
John M. Newsam
Dominic King-Smith
Edward Kisak
Original Assignee
Nuvo Research Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nuvo Research Inc. filed Critical Nuvo Research Inc.
Publication of WO2011014850A2 publication Critical patent/WO2011014850A2/en
Publication of WO2011014850A3 publication Critical patent/WO2011014850A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention provides topical compositions, methods of preparation, and methods of treatment involving the incorporation of a eutectic melt into a formulation. The improved formulation can enhance permeability and bioavailability. In certain specific embodiments, the invention provides an anti-fungal pharmaceutical composition for topical application comprising an anti-fungal agent, at least one eutectic agent, and a pharmaceutically acceptable low-boiling solvent.
PCT/US2010/044036 2009-07-31 2010-07-30 Topical eutectic-based formulations WO2011014850A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23047309P 2009-07-31 2009-07-31
US61/230,473 2009-07-31

Publications (2)

Publication Number Publication Date
WO2011014850A2 WO2011014850A2 (en) 2011-02-03
WO2011014850A3 true WO2011014850A3 (en) 2011-11-17

Family

ID=42634505

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/044036 WO2011014850A2 (en) 2009-07-31 2010-07-30 Topical eutectic-based formulations

Country Status (1)

Country Link
WO (1) WO2011014850A2 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2544659A2 (en) * 2009-12-23 2013-01-16 Nuvo Research Inc. Highly permeating terbinafine formulation for treating onychomycosis
EP2664327A1 (en) * 2012-05-14 2013-11-20 Almirall S.A. Topical pharmaceutical compositions comprising terbinafide and urea
EA030797B1 (en) 2012-12-21 2018-09-28 ТЕЙКОКУ ФАРМА ЮЭсЭй, ИНК. System for transdermal delivery of hormones (embodiments) and methods for use thereof
US9446131B2 (en) 2013-01-31 2016-09-20 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
US9452173B2 (en) 2013-01-31 2016-09-27 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
US9433680B2 (en) 2013-01-31 2016-09-06 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
US8778365B1 (en) 2013-01-31 2014-07-15 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
US11241520B2 (en) * 2014-08-07 2022-02-08 Cook Medical Technologies Llc Compositions and devices incorporating water-insoluble therapeutic agents and methods of the use thereof
US10272054B2 (en) 2015-10-07 2019-04-30 Exodos Life Sciences Lp Topical antifungal compositions
WO2017216722A2 (en) * 2016-06-13 2017-12-21 Vyome Biosciences Pvt. Ltd. Synergistic antifungal compositions and methods thereof
BR112018075998A2 (en) * 2016-06-13 2019-04-02 Vyome Therapeutics Limited. synergistic antifungal compositions and methods thereof
FR3058905B1 (en) * 2016-11-18 2020-02-28 Universite Du Littoral Cote D'opale PROCESS FOR THE PURIFICATION OF A GASEOUS EFFLUENT
WO2019214838A1 (en) * 2018-05-09 2019-11-14 Eviderm Institute Ab Use of an alcohol-containing composition for improving the skin barrier function
EP3870227B1 (en) * 2018-10-24 2022-12-21 SeraNovo B.V. Deep eutectic solvent platform for oral pharmaceutical formulations
WO2020223093A1 (en) * 2019-04-30 2020-11-05 Bayer Healthcare Llc Topical analgesic gel compositions
US20200345696A1 (en) * 2019-04-30 2020-11-05 Bayer Healthcare Llc Topical Analgesic Compositions
NL2023661B1 (en) 2019-08-19 2021-04-21 Seranovo Holding B V Pharmaceutical Eutectic Salt Formulation
CA3157201A1 (en) * 2019-10-08 2021-04-15 Hallux Inc. Onychomycosis treatment compositions and methods
CN115867368A (en) * 2020-07-10 2023-03-28 阿克福特斯技术有限公司 Solvent drying solution and method thereof
CN113024362B (en) * 2021-03-10 2022-02-15 中国科学院上海药物研究所 Co-crystal of coenzyme QH and nicotinamide, preparation method and application thereof
CN114949324B (en) * 2022-06-15 2024-02-02 浙江工业大学 Preparation method of biocompatible antibacterial gel film
WO2023245256A1 (en) * 2022-06-24 2023-12-28 Royal Melbourne Institute Of Technology Antimicrobial gels

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0197076A1 (en) * 1984-10-08 1986-10-15 Durst Phototechnik Gmbh Photographic enlarger or copying machine for colour prints.
EP0503988A1 (en) * 1991-03-08 1992-09-16 Sandoz Ltd. Compositions to treat onychomycoses
WO2004084826A2 (en) * 2003-03-21 2004-10-07 Nexmed Holdings, Inc. Antifungal nail coat and method of use
WO2005018530A2 (en) * 2003-08-25 2005-03-03 Foamix Ltd. Penetrating pharmaceutical foam
US20060078599A1 (en) * 2004-10-12 2006-04-13 Mathew Ebmeier Pharmaceutical composition applicable to body tissue

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7713618L (en) 1977-12-01 1979-06-02 Astra Laekemedel Ab LOCAL ANESTHETIC MIXTURE
US6368618B1 (en) 1999-07-01 2002-04-09 The University Of Georgia Research Foundation, Inc. Composition and method for enhanced transdermal absorption of nonsteroidal anti-inflammatory drugs
US20070224261A1 (en) 2006-03-22 2007-09-27 Peter Draper Eutectic liquid drug formulation

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0197076A1 (en) * 1984-10-08 1986-10-15 Durst Phototechnik Gmbh Photographic enlarger or copying machine for colour prints.
EP0503988A1 (en) * 1991-03-08 1992-09-16 Sandoz Ltd. Compositions to treat onychomycoses
WO2004084826A2 (en) * 2003-03-21 2004-10-07 Nexmed Holdings, Inc. Antifungal nail coat and method of use
WO2005018530A2 (en) * 2003-08-25 2005-03-03 Foamix Ltd. Penetrating pharmaceutical foam
US20060078599A1 (en) * 2004-10-12 2006-04-13 Mathew Ebmeier Pharmaceutical composition applicable to body tissue

Also Published As

Publication number Publication date
WO2011014850A2 (en) 2011-02-03

Similar Documents

Publication Publication Date Title
WO2011014850A3 (en) Topical eutectic-based formulations
BR112014031773A2 (en) biodegradable drug delivery for hydrophobic compositions
WO2012021715A3 (en) Stable formulations of linaclotide
WO2008132229A3 (en) Highly concentrated insulin solutions and compositions
EP2344198A4 (en) Lipid based pharmaceutical preparations for oral and topical application; their compositions, methods, and uses thereof
WO2010021607A3 (en) Pharmaceutical formulation
WO2006099169A3 (en) Novel liposome compositions
ZA200809864B (en) Pharmaceutical formulations for the sustained release of active ingredients(s), as well as their applications, especially therapeutic
WO2006138735A3 (en) Gel compositions for topical administration
WO2011141685A3 (en) Systemic nasal compositions comprising cocoyl proline or at least one of the constituents thereof
EP2102225A4 (en) Alpha-galactosylceramide derivatives, pharmaceutically acceptable salts thereof, preparation method and pharmaceutical composition for the immune adjuvant containing the same as an active ingredient
WO2007133751A3 (en) Base-stabilized polyorthoester formulations
WO2006094799A3 (en) Pyridinone derivatives against malaria
WO2011019326A3 (en) Solubility and stability enchancing pharmaceutical formulation
WO2010049449A3 (en) Novel salts of sunitinib
WO2012053009A3 (en) Pharmaceutical compositions comprising nano size droplets of skin whitening agents
WO2008129501A3 (en) Pharmaceutical compositions of duloxetine
WO2011002422A3 (en) Solubility enhancing pharmaceutical formulation
WO2012085284A3 (en) High drug load pharmaceutical formulations comprising dronedarone and its pharmaceutically acceptable salts
WO2011060195A3 (en) Topical etoricoxib formulation comprising an eutectic mixture of permeation enhancers
WO2014064652A3 (en) Stable pharmaceutical composition of peginterferon alpha-2b
WO2011064558A3 (en) Pharmaceutical composition
WO2011076209A3 (en) Pharmaceutical composition comprising solvent mixture and a vitamin d derivative or analogue
IL210975A (en) Enfumafungin derivatives, pharmaceutical compositions comprising them and use thereof for the preparation of medicaments for treating fungal infections
WO2009084036A3 (en) Composition for treatment of viral infections

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10740814

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10740814

Country of ref document: EP

Kind code of ref document: A2